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The ALAD gene codes for the enzyme
δ-aminolevulinic acid dehydratase (ALAD),
which catalyzes the second step of heme syn-
thesis involving the condensation of two
molecules of aminolevulinic acid (ALA) to
form porphobilinogen. The most commonly
studied polymorphism in the gene, ALAD
G177C (dbSNP ID: rs1800435) contains a
G-to-C transversion at position 177 of the
coding region, resulting in the substitution of
asparagine for lysine. ALAD G177C has two
codominant alleles: ALAD1 and ALAD2
(Battistuzzi et al. 1981), with an ALAD2 allele
prevalence of approximately 10% (range,
6–20%) in Caucasian populations, 3–11% in
Asian populations, and 3% in African-
American populations (Kelada et al. 2001).
Although ALAD can be inhibited by a
variety of chemicals, including lead, trichloro-
ethylene, bromobenzene, and styrene (Fujita
et al. 2002), polymorphic differences in
enzyme binding or chemical uptake have been
examined most extensively for lead. On aver-
age, individuals with the ALAD2 allele have
higher blood lead levels than do ALAD1
homozygotes, probably due to tighter binding
of lead by the ALAD2 enzyme (Alexander
et al. 1998; Bergdahl et al. 1997; Fleming et al.
1998; Hsieh et al. 2000; Shen et al. 2001;
Wetmur et al. 1991; Ziemsen et al. 1986).
Previous studies in animals and humans indi-
cate that exposure to lead may increase the risk
of brain tumors [International Agency for
Research on Cancer (IARC) 1987; Silbergeld
2003; Steenland and Boffetta 2000], particu-
larly meningioma (Cocco et al. 1999; Hu et al.
1999; Navas-Acien et al. 2002).
Given that the ALAD G177C poly-
morphism affects the toxicokinetics of lead in
the body, and that exposure to lead may
increase the risk of adult brain tumors, we
postulated a possible association of ALAD
G177C genotype and risk of intracranial
tumors of the brain and nervous system (here-
after referred to as brain tumors). Analyses
were conducted using data from a hospital-
based case–control study of brain tumors con-
ducted by the National Cancer Institute
(NCI) between 1994 and 1998.
Materials and Methods
Study population. Subjects for the brain
tumor study were enrolled from 1994
through 1998 from three hospitals specializ-
ing in brain tumor treatment, located in
Phoenix, Arizona; Boston, Massachusetts;
and Pittsburgh, Pennsylvania. The study pro-
tocol was approved by the institutional review
board of each participating institution. Study
methods have been described in detail else-
where (Inskip et al. 2001).
Eligible cases for the parent study were
≥ 18 years of age with a first intracranial
glioma, meningioma, or acoustic neuroma
diagnosed during or within the 8 weeks pre-
ceding hospitalization. Ninety-two percent
of eligible brain tumor patients agreed to
participate in the study. All diagnosed cases
of glioma and meningioma were confirmed
by microscopy, as were 96% of acoustic
neuroma cases. A total of 489 subjects with
glioma, 197 subjects with meningioma, and
96 subjects with acoustic neuroma were
enrolled.
Controls were patients admitted to the
same hospitals as cases for a variety of non-
neoplastic conditions, with the most common
being injuries (25%), circulatory system dis-
orders (22%), musculoskeletal disorders
(22%), and digestive disorders (12%). More
than 90% of patients were interviewed within
1 year of symptom onset. Control subjects
were frequency matched in a 1:1 ratio to all
brain tumor cases based on hospital, age, sex,
race/ethnicity, and proximity of residence to
the hospital; 799 controls (86% of all con-
tacted controls) were enrolled.
Informed written consent was obtained
from all cases and controls. Blood samples
were collected and sent for genotyping for
73% of all subjects: 382 subjects with glioma
(78%), 158 subjects with meningioma (80%),
71 subjects with acoustic neuroma (74%), and
540 control subjects (68%). The main obsta-
cle to obtaining blood samples was subject
refusal, with nonparticipation in the blood
draw being higher for control subjects than for
case subjects.
Shortly after hospitalization, a trained
research nurse administered a structured in-
person interview for each subject. Information
on known or possible risk factors for brain
tumors (including a detailed occupational
history) was collected for all subjects.
Processing of blood samples. DNA was
extracted from the peripheral white blood cells
(buffy coat or granulocytes) of blood samples
using a phenol-chloroform method described
by Daly et al. (1996). ALAD genotyping was
conducted by the NCI’s Core Genotyping
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The enzyme δ-aminolevulinic acid dehydratase (ALAD), which catalyzes the second step of heme
synthesis, can be inhibited by several chemicals, including lead, a potential risk factor for brain
tumors, particularly meningioma. In this study we examined whether the ALAD G177C poly-
morphism in the gene coding for ALAD is associated with risk of intracranial tumors of the brain
and nervous system. We use data from a case–control study with 782 incident brain tumor cases
and 799 controls frequency matched on hospital, age, sex, race/ethnicity, and residential proximity
to the hospital. Blood samples were drawn and DNA subsequently sent for genotyping for 73% of
subjects. ALAD genotype was determined for 94% of these samples (355 glioma, 151 meningioma,
67 acoustic neuroma, and 505 controls). Having one or more copy of the ALAD2 allele was associ-
ated with increased risk for meningioma [odds ratio (OR) = 1.6; 95% confidence interval (CI),
1.0–2.6], with the association appearing stronger in males (OR = 3.5; 95% CI, 1.3–9.2) than in
females (OR = 1.2; 95% CI, 0.7–2.2). No increased risk associated with the ALAD2 variant was
observed for glioma or acoustic neuroma. These findings suggest that the ALAD2 allele may
increase genetic susceptibility to meningioma. Key words: ALAD, brain, case–control, meningioma,
polymorphism, tumor. Environ Health Perspect 113:1209–1211 (2005). doi:10.1289/ehp.7986
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assay (Applied Biosystems, Foster City, CA).
Reactions for the assay were done in a 384
(96 × 4)-well plate format. Lyophilized sample
DNA (10 ng) was used for a 5 µL TaqMan
reaction. Four Coriell DNA controls (Coriell
Cell Repositories, Camden, NJ) for each geno-
type as well as no-template controls (NTCs)
were put on the plate along with the samples;
2.5 µL of the 2X Universal Master Mix
(Applied Biosystems), 200 nM of each primer,
and 900 nM of each probe was used in the
reaction. Probe 1 (TGTGAAGCGGCTGG),
specific to the ALAD1 allele, contained the
FAM dye reporter. Probe 2 (TGTGAAC-
CGGCTGG) was speciﬁc to the ALAD2 allele
and contained the VIC dye reporter. The
primers used were primers F (TGCCTTC-
CTTCAACCCCTCTA) and R (CAAGG-
GCCTCAGCATCTCTT). Step 1 of the
assay-speciﬁc thermocycling process involved
2 min of UNG (uracil-DNA glycosylase) acti-
vation using AmpErase UNG (Applied
Biosystems) at 50°C. This was followed by
10 min of enzyme activation at 95°C (step 2),
0.30 sec of template denaturation at 92°C if
using 3´MGB quencher, or at 95°C if using
3´TAMRA quencher (step 3), and 1 min of
assay-specific annealing at 60°C (step 4).
Steps 3 and 4 were repeated 49 times, after
which the reaction was held at 4°C. The plate
was then read on the ABI 7900HT sequence
detection system (Applied Biosystems), and the
results of the allelic discrimination were
graphed as a scatter plot of allele 1 reaction ver-
sus allele 2 reaction (SDS Software; Applied
Biosystems), with each well of the 384-well
plate represented as a spot on the graph. Four
distinct clusters on the allelic plot represented
the NTCs and three possible genotypes,
ALAD1–1, ALAD2–2, and ALAD1–2, respec-
tively. Calls were determined manually by a
technician using SDS software.
Quality control specimens for the study
included multiple samples from three individ-
uals who were not study subjects (QC-A,
n = 34; QC-B, n = 20; QC-C, n = 15) and
76 duplicates from study subjects. These
specimens were submitted for genotyping in a
masked fashion and were collected and
processed in a manner identical to that for
study samples. Ninety-eight percent agree-
ment was achieved between the three non-
study replicates. The concordance rate for
study duplicates (study samples compared
with masked relabels) was 87% for glioma,
100% for meningioma, 85% for acoustic
neuroma, and 89% for controls.
Using a conservative call strategy that
labeled a call as missing if the genotype was
unclear, ALAD genotyping was successfully
conducted for 94% of samples (93% of
gliomas, 96% of meningiomas, 94% of acoustic
neuromas, and 94% of controls). Missing val-
ues (noncalls) were generally equally likely to
be from case or control samples.
Statistical analysis. We assessed statistically
significant departure from Hardy-Weinberg
equilibrium for controls using the chi-square
test. Unconditional logistic regression was used
to estimate odds ratios (ORs) and calculate
95% conﬁdence intervals (CIs) for the effect of
the variant ALAD2 allele, adjusting for study
matching factors. We entered adjustment vari-
ables as indicator variables in the following cat-
egories: age in years (18–29, 30–39, 40–49,
50–59, 60–69, 70–79, 80–99); race/ethnicity
(non-Hispanic white, Hispanic, African-
American, other); sex (male, female); hospital
(Phoenix, Boston, Pittsburgh); and residential
proximity to the hospital in miles (0–4, 5–14,
15–29, 30–49, ≥ 50). Because the small num-
ber of ALAD2–2 homozygotes precluded
accurate estimation of risk for ALAD1–2
heterozygotes and ALAD2–2 homozygotes
separately, these categories were combined for
analysis. ALAD1–1 homozygotes were the ref-
erence group. In order to test for the influ-
ence of control group composition on the
results, the models were run excluding each
major category of control discharge diagnosis,
one at a time.
Results
The distribution of demographic characteris-
tics for genotyped subjects (Table 1) was com-
parable with the distribution for all study
subjects (Inskip et al. 2001). Most demo-
graphic characteristics were distributed simi-
larly for brain tumor cases and controls.
Relative to controls, subjects with glioma were
proportionately more often male, whereas sub-
jects with meningioma and acoustic neuroma
were more often female. Differences between
individual tumor group and control group dis-
tributions were mostly due to the matching of
controls for all tumors combined rather than
for speciﬁc tumor subgroups.
Study participants in the youngest and
oldest age brackets were less likely to have
given a blood sample, as were control subjects
who lived closest to the hospital. Brain tumor
cases that were male, of “other” race/ethnicity,
or from the Phoenix study site were also
less likely to have given a blood sample (results
not shown).
No significant departure from Hardy-
Weinberg equilibrium was detected for con-
trols (p = 0.3). Table 2 summarizes the
association between ALAD G177C genotype
and risk of each brain tumor type. The odds
of meningioma were significantly higher for
individuals possessing any ALAD2 allele com-
pared with ALAD1–1 homozygotes (OR =
1.6; 95% CI, 1.0–2.6). This risk did not dif-
fer markedly when different control sub-
groups (musculoskeletal disorders, circulatory
disorders, digestive disorders, or trauma) were
excluded. Although the observed association
between ALAD2 and meningioma appeared
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Table 1. Demographic characteristics for individuals with glioma, meningioma, and acoustic neuroma and
frequency-matched controlsa for genotyped individuals: NCI adult brain tumor study, 1994–1998.
Glioma cases Meningioma Acoustic neuroma Controls
Characteristic (n = 355) cases (n = 151) cases (n = 67) (n = 505)
Sex
Male 192 (54.1) 32 (21.2) 23 (34.3) 234 (46.3)
Female 163 (45.9) 119 (78.8) 44 (65.7) 271 (53.7)
Race/ethnicity
White, non-Hispanic 323 (91.0) 123 (81.5) 61 (91.0) 450 (89.1)
Hispanic 19 (5.4) 12 (8.0) 5 (7.5) 36 (7.1)
Black 7 (2.0) 9 (6.0) 0 (0.0) 11 (2.2)
Other 6 (1.7) 7 (4.6) 1 (1.5) 8 (1.6)
Mean age (years) 51.3 55.0 51.6 49.4
Hospital site
Phoenix, AZ 162 (45.6) 75 (49.7) 49 (73.1) 258 (51.1)
Boston, MA 126 (35.5) 62 (41.1) 18 (26.8) 164 (32.5)
Pittsburgh, PA 67 (18.9) 14 (9.3) 0 (0.0) 83 (16.4)
Values are no. (%) except where indicated.
aControls were matched to the total case group including glioma, meningioma, and acoustic neuroma.
Table 2. Association of ALAD2 polymorphism (ALAD1–2 or ALAD2–2) with risk of glioma, meningioma, and
acoustic neuroma: NCI adult brain tumor study, 1994–1998.a
Glioma Meningioma Acoustic neuroma Control
(n = 355) (n = 151) (n = 67) (n = 505)
No. (%)b OR (95% CI) No. (%) OR (95% CI) No. (%) OR (95% CI) No. (%)
ALAD1–1 301 (84.8) 1.0  116 (76.8) 1.0  57 (85.1) 1.0  420 (83.2)
ALAD1–2 53 (14.9) 0.9 (0.6–1.3)c 32 (21.2) 1.6 (1.0–2.6)c 10 (14.9) 0.9 (0.4–1.9)c 79 (15.6)
ALAD2–2 1 (0.3) 3 (2.0) 0 6 (1.2)
aModels adjusted for matching factors (hospital, sex, race/ethnicity, age, residential proximity to hospital); results are
only reported if number of exposed cases is ≥ 5. bPercentages based on genotyped samples. cEstimates are for having
≥ 1 copy of the ALAD2 allele.stronger in males (OR = 3.5; 95% CI,
1.3–9.2) than in females (OR = 1.2; 95% CI,
0.7–2.2), the sample size for the sex-specific
estimates was small, with only 10 male and
25 female meningioma cases possessing the
variant allele. No increased risk associated
with the ALAD2 variant was observed for
glioma or acoustic neuroma.
Discussion
We found that the ALAD2 allele of the G177C
polymorphism was associated with increased
risk of meningioma, especially in males.
Conﬁrmation of our ﬁndings will require repli-
cation in other studies with a larger number of
meningioma cases. If risk of meningioma is
truly increased in individuals with the ALAD2
allele, the question arises as to whether the
effect depends upon exogenous chemical expo-
sures that act on the heme synthesis pathway or
is independent of such exposures. A direct effect
of the ALAD2 polymorphism might be indi-
cated if the ALAD2 allele has lower enzyme
activity than the ALAD1 allele, given that the
precursor ALA is thought to be neurotoxic and
genotoxic (Silbergeld 2003). However, ALAD
enzyme activity does not appear signiﬁcantly
different for the two alleles (Battistuzzi et al.
1981). Alternatively, it is possible that the
increased risk of meningioma in ALAD2 indi-
viduals arises in the presence of chemicals that
inﬂuence the heme synthesis pathway. Several
chemicals have been shown to inhibit ALAD
enzyme activity, including lead, trichloro-
ethylene, bromobenzene, and styrene (Fujita
et al. 2002). Polymorphic differences in enzyme
binding or chemical uptake have been exam-
ined most extensively for lead, and individuals
with the ALAD2 allele are generally reported to
have higher blood lead levels than are individu-
als with the ALAD1 allele (Alexander et al.
1998; Bergdahl et al. 1997; Fleming et al.
1998; Hsieh et al. 2000; Shen et al. 2001;
Wetmur et al. 1991; Ziemsen et al. 1986).
The observation that the relationship
between ALAD2 and risk of meningioma was
stronger in men than in women could be due
to biologic differences or differential exposure
to a chemical agent modiﬁed by ALAD geno-
type. Given the small number of male menin-
gioma cases with the variant allele, we also
cannot rule out the possibility that the
observed effect modiﬁcation is due to chance.
The speciﬁc question of ALAD genotype
and brain tumor risk has not been addressed
previously in the literature. In a previously
published analysis of this same data set, we
found elevated risk of meningioma in individ-
uals who had worked in military occupations
or as autobody painters, designers and decora-
tors, industrial production supervisors, teach-
ers, or managers (Rajaraman et al. 2004).
Aside from teachers and managers, all of these
occupations have potential exposure to lead,
suggesting that lead might be implicated in
meningioma risk. Our observation of increased
risk with the ALAD2 variant for meningioma,
but not for glioma or acoustic neuroma, paral-
lels the observation that reports of increased
risk of brain tumor with lead have been more
consistent for meningioma (Cocco et al. 1999;
Hu et al. 1999; Navas-Acien et al. 2002) than
for glioma or for all brain tumors combined.
However, the role of lead in the observed
association between ALAD genotype and
meningioma can be meaningfully addressed
only when data on both ALAD genotype and
individual lead exposure are available.
In a study with hospital controls, study
results can be biased if the exposure under
study is associated with conditions enrolled
in the control series (Miettinen 1985). To
assess for such a bias, we conducted a sensi-
tivity analysis by excluding one major control
subgroup at a time from the analysis.
Systematically excluding control subgroups
did not change observed ORs appreciably and
resulted, if anything, in slightly stronger evi-
dence of an association between ALAD2 and
meningioma when circulatory or digestive
disorders were excluded. If use of hospital
controls introduced a bias in the observed
OR, therefore, the likely direction of the bias
was toward the null.
The relatively low concordance rate for
study duplicates is another potential concern.
However, the concordance for duplicates from
meningioma cases was 100%, so our observed
association for meningioma was probably not
affected by genotyping concerns. Moreover, if
we assume that 10% nondifferential mis-
classiﬁcation did occur, this would have biased
our findings toward the null, making our
observed association a conservative estimate.
We chose to study the ALAD poly-
morphism based on a priori biologic and func-
tional considerations and not by screening a
large number of associations. Nonetheless, the
possibility that our ﬁndings are due to chance
cannot be ruled out. These ﬁndings should be
viewed as hypothesis generating and need to
be conﬁrmed by replication in other studies.
Although our study had limited power for
evaluating risk with respect to subtypes of
tumor, it remains one of the largest case–
control studies of brain tumors to date. Aside
from a small percentage of brain tumors that
can be explained by familial syndromes or
exposure to ionizing radiation, very little is
known about the etiology of brain tumors
(Preston-Martin and Mack 1996; Wrensch
et al. 2002). In order to clarify the role of lead
(or other chemicals) in the observed relation-
ship between ALAD genotype and risk of
meningioma, it will be important to conduct a
detailed exposure assessment and evaluate the
joint effect of exposure and ALAD genotype in
this, or another, study population.
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